Trial · NCT02258542
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 42
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in hematologic lab parameter of Basophils. |
| Primary | Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Basophils. |
| Primary | Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in hematologic lab parameter of Leukocytes. |
| Primary | Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Leukocytes. |
| Primary | Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in hematologic lab parameter of Lymphocytes. |
| Primary | Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Lymphocytes. |
| Primary | Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in hematologic lab parameter of Neutrophils. |
| Primary | Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Neutrophils. |
| Primary | Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in hematologic lab parameter of Eosinophils. |
| Primary | Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Eosinophils. |
| Primary | Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in chemistry tests ALT. |
| Primary | Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of ALT. |
| Primary | Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in chemistry tests AST. |
| Primary | Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of AST. |
| Primary | Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients | Week 56 | Change from baseline in chemistry test Bilirubin. |
| Primary | Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline in hematologic lab parameter of Bilirubin. |
| Secondary | Number of Overall Patients With Asthma Exacerbations During Study Period | From week 0 to week 56 in study treatment period and through the follow up period (16 weeks from day of last dose) | Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit |
| Secondary | Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA) | From week 0 to week 108 in study treatment period and through the follow up period (16 weeks from day of last dose) | Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit |
| Secondary | Change From Baseline in Pre-bronchodilator FEV1 (L) | Week 56 | Change from baseline to Week 56 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1). |
| Secondary | Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA) | Week 108 | Change from baseline to Week 108 in Pre-bronchodilator Forced expiratory volume in 1 second (FEV1). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02258542/registered